Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection

Journal of Clinical Gastroenterology

Volumn 42, Issue 2, 2008, Pages 139-142

  Murakami, Kazunari ^a   Okimoto, Tadayoshi ^a   Kodama, Masaaki ^a   Sato, Ryugo ^a   Watanabe, Koichiro ^a   Fujioka, Toshio ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Clarithromycin resistance; Metronidazole resistance; Proton pump inhibitor; Retreatment

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; DRUG SENSITIVITY; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETREATMENT;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AMOXICILLIN; ANTI-INFECTIVE AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; OMEPRAZOLE; PEPTIC ULCER; PROTON PUMP INHIBITORS; RETREATMENT; TREATMENT OUTCOME;

EID: 38349125405     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31802cbc1a     Document Type: Article

References (18)

1. Asaka M, Kato M, Sugiyama T, et al. Follow-up survey of a large-scale multi-center, double-blind study on triple therapy with lansoprazole, amoxycillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. J Gastroenterol. 2003;38:339-347.
2. Vakil N, Hahn B, McSoley D. Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. Am J Gastroenterol. 1998;93:1423-1435.
3. Adamek RJ, Suerbaum S, Phaffenbach B, et al. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin - influence on treatment outcome. Am J Gastroenterol. 1998;93:386-389.
4. Asaka M, Satoh K, Sugano K, et al. Guidelines in the management of Helicobacter pylori infection in Japan. Helicobacter. 2001;6:177-186.
5. The European Helicobacter Pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut. 1997;41:8-13.
6. Nagahara A, Miwa H, Ohkura R, et al. Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection. J Gastroenterol Hepatol. 2001;16:613-618.
7. Murakami K, Sato R, Fujioka T, et al. Efficacy of triple therapy comprising rabeprazole amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment Pharmacol Ther. 2003;17:119-123.
8. Isomoto H, Inoue K, Furusu H, et al. High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection. Aliment Pharmacol Ther. 2003;18:101-107.
9. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther. 1999;13(suppl. 3):27-36.
10. Adachi K, Katsube T, Kinosita Y, et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther. 2000;14:1259-1266.
11. Furuta T, Ohashi K, Kaneko E, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med. 1998;129:1027-1030.
12. Murakami K, Sato R, Fujioka T, et al. Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Aliment Pharmacol Ther. 2002;16:1933-1938.
13. Narikawa S. Distribution of metronidazole susceptibility factors in obligate anaerobes. J Antimicrob Chemother. 1986;18:565-574.
14. Sachs G, Meyer-Rosberg K, Scott DR, et al. Acid, protons and Helicobacter pylori. Yale J Biol Med. 1996;69:301-316.
15. Murakami K, Fujioka T, Okimoto T, et al. Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy. Int J Antimicrob Agents. 2002;19:67-70.
16. Kato M, Yamaoka Y, Kim JJ, et al. Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother. 2000;44:2214-2216.
17. Furuta T, Shirai N, Xiao F, et al. High-dose rabeprazole/amoxillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003;50:2274-2278.
18. Murakami K, Sato R, Okimoto T, et al. Effectiveness of minocycline-based triple therapy for eradication of Helicobacter pylori infection. J Gastroenterol Hepatol. 2006;21:262-267.